We extend our commitment to critical care through a focused, patient-centric approach to intensive therapy. Cadila Pharma’s dedicated critical care division delivers high-quality, evidence-based therapies to critically ill patients, ensuring effective and reliable treatment.

Our therapeutic focus
We offer a comprehensive portfolio of high-quality, evidence-based medicines across multiple therapeutic segments. All products in the portfolio are developed at our world-class, regulatory-compliant manufacturing facilities in Dholka and at our Udaipur Plant, which is one of the largest in Asia and adheres to the highest global standards, further building our lyophilised product manufacturing capabilities at par with international quality standards.




Contact Us
Our Story
Businesses
Therapies
Corporate Identification No : U24231GJ1991PLC015132
©2026 Cadila Pharmaceuticals. All rights reserved